OSR Holdings, Inc. (OSRH)

NCM – Real vaqt narxi. Valyuta: USD

0.33

+0.01 (4.18%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

0.33

-0.00 (-1.44%)

Bozordan keyin: Jun 26, 2026, 7:36 PM EDT

03.06.2026

CEO Statement to Shareholders

BELLEVUE, WA / ACCESS Newswire / June 3, 2026 / Dear Fellow Shareholders, As we move through 2026, I would like to provide an update on where OSR Holdings (NASDAQ:OSRH) stands today and how we are approaching the opportunities ahead: Strategic Focus and Business Development Over the past year, we have continued to strengthen our position as a biomedical holding company with a growing portfolio of innovative businesses spanning oncology, regenerative medicine, medical devices, and digital health. We are seeing increasing external validation of the technologies and platforms being developed by our subsidiaries.

27.05.2026

OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million Transaction

Transaction Centralizes VXM01 Ownership and Long-Term Royalty Economics at the OSRH Parent Level BELLEVUE, WA / ACCESS Newswire / May 27, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding company focused on innovative therapeutics and healthcare technologies, today announced it has entered into a definitive Asset Purchase Agreement ("APA") with VAXIMM AG ("Vaximm") to acquire the full global intellectual property portfolio and related assets for an aggregate purchase price of $30 million. The acquisition follows OSRH's previously announced definitive global exclusive license agreement with BCM Europe AG ("BCME") for VXM01, which includes up to $815 million in milestone payments tied to the development and commercialization of the program.

12.05.2026

CEO Statement to Shareholders

A Clear Commitment: No Reverse Stock Split BELLEVUE, WA / ACCESS Newswire / May 12, 2026 / As many of our shareholders are aware, OSR Holdings filed its Preliminary Proxy Statement on Schedule PRE 14A with the U.S. Securities and Exchange Commission on May 11, 2026. Given the proximity of our Nasdaq minimum bid compliance deadline, we believe it is important to provide direct and unambiguous transparency regarding our strategy.

05.05.2026

Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target

NEW YORK, NY / ACCESS Newswire / May 5, 2026 / Emerging Growth Research today issued a flash report on OSR Holdings, Inc. (Nasdaq:OSRH), reaffirming its Buy-Emerging rating and 12-month price target of $10.00. The flash report highlights OSRH's execution of an $815 million definitive exclusive license agreement with BCM Europe AG (BCME) for the global development, commercialization, and out-licensing of VXM01 - a Phase-2b/3 ready oral immunotherapy for glioblastoma multiforme (GBM) and pancreatic cancer.

30.04.2026

OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026

OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026 BELLEVUE, WA / ACCESS Newswire / April 30, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding company advancing biomedical innovations to improve health and wellness worldwide, today announced that management will present at the upcoming Emerging Growth Conference. The presentation will provide investors and analysts with an overview of the Company's landmark VXM01 global licensing agreement and its implications for OSRH shareholders.

29.04.2026

OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe

Largest shareholder pledges entire equity stake as collateral for milestone obligations, reinforcing alignment with public shareholders BELLEVUE, WA / ACCESS Newswire / April 29, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) today announced that it has entered into a definitive global exclusive license agreement (the "Agreement") with BCM Europe AG ("BCME") for the development, commercialization, and potential sublicensing of VXM01, its Phase 3-ready oral immunotherapy targeting VEGFR-2. The Agreement builds on the previously disclosed binding term sheet and establishes a structured framework to advance VXM01, with alignment across OSRH, its largest shareholder BCME, and public shareholders.

09.04.2026

OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note

BELLEVUE, WA / ACCESS Newswire / April 9, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) ("OSR Holdings" or the "Company") today announced a strategic transaction for capital structure optimization with White Lion GBM Innovation Fund ("White Lion"), centered on the retirement of approximately $2.02 million of warrant overhang. Elimination of $2.02 Million Warrant Overhang As part of the transaction, OSR Holdings has retired approximately $2.02 million of outstanding warrants by consolidating them into a newly issued convertible promissory note.

Videolar

No Data

There is no data to display

Press-relizlar

03.06.2026

OSR Holdings, Inc. (OSRH)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

OSR Holdings, Inc. (OSRH)

CEO Statement to Shareholders

OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million Transaction

CEO Statement to Shareholders

Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target

OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026

OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe

OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note

Videolar

No Data

Press-relizlar

CEO Statement to Shareholders

CEO Statement to Shareholders

OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million Transaction

CEO Statement to Shareholders

Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target

OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026

OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe

OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note

Videolar

No Data

Press-relizlar

CEO Statement to Shareholders

OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million Transaction

CEO Statement to Shareholders

Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target

Search stocks

OSR Holdings, Inc. (OSRH)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

OSR Holdings, Inc. (OSRH)

CEO Statement to Shareholders

OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million Transaction

CEO Statement to Shareholders

Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target

OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026

OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe

OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note

Videolar

No Data

Press-relizlar

CEO Statement to Shareholders

CEO Statement to Shareholders

OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million Transaction

CEO Statement to Shareholders

Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target

OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026

OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe

OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note

Videolar

No Data

Press-relizlar

CEO Statement to Shareholders

OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million Transaction

CEO Statement to Shareholders

Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target